Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ketol-acid reductoisomerase (KARI) is a magnesium-dependent, NADPH-utilizing bifunctional enzyme that catalyzes two sequential reactions in the biosynthesis of branched-chain amino acids (valine, leucine, and isoleucine) in bacteria, plants, and fungi but not in animals[1][2][3][4][5]. It orchestrates an alkyl migration (isomerization) followed by a reductive step using NADPH[2][3]. There are two main KARI classes: the short form, found in fungi and many bacteria, and the long form, found in plants and some bacteria[1][2]. The enzyme is essential for growth and survival in organisms that rely on de novo synthesis of branched-chain amino acids[4]. KARI is the target of several herbicides and is under investigation as a potential antibacterial and antifungal target given its absence in animal metabolism[4][7][8]. Structurally, KARI forms oligomeric assemblies (dimers, tetramers, or dodecamers) and relies on conserved residues to coordinate metal ions and catalyze the reaction[1][3]. Inactivation of KARI disrupts branched-chain amino acid synthesis, leading to growth arrest in sensitive organisms[4]. KARI’s unique role in non-animal organisms makes it an attractive target in agriculture and anti-infective research.
Competitive inhibition of substrate binding or cofactor (NADPH or Mg2+) binding; Disruption of branched-chain amino acid biosynthesis, leading to amino acid starvation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ketol-acid reductoisomerase (KARI).